Top-level science through the eyes of an expert.
The sixth Webinar.
The sixth webinar in the Naked Immunology series is now scheduled on October 12, 2023 at 8 a.m. (PST), 11 a.m. (EST), 5 p.m. (CET). The webinar is open to English-speaking participants with a solid scientific background. Featured speaker is Dr. Laurent Reber, Laboratory Director at the Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy, France) and Principal Investigator at the French National Institute of Health and Medical Research (INSERM, France).
In this webinar, Dr. Reber will focus on the development and potential of kinoid vaccines that target IL-4, IL-13, and IgE to provide long-term protection against allergic asthma and anaphylaxis.
The incidence of allergies has dramatically increased over the last three decades in industrialized countries. Among all allergies, allergic asthma and food allergy are major public health problems now each affecting more than 220 million people worldwide. Allergies are considered to result from a breakdown of tolerance, resulting in type 2 immune responses characterized by the production of TH2 cytokines such as IL-4 and IL-13, high levels of IgE antibodies, and infiltration and expansion of immune cells (in particular mast cells, basophils, eosinophils and T cells) within the inflamed tissue. Therapeutic antibodies targeting the IL-4/IL-13 or IgE pathways are approved for the treatment of allergic asthma and in clinical evaluation for other allergic diseases, but are costly and require frequent reinfusions in order to maintain clinical efficacy.
Dr. Reber will present recent data resulting from a collaborative project between the French biotech NEOVACS, the INSERM and Institut Pasteur, in which they developed conjugate vaccines, named kinoids, directed against IL-4, IL-13 or IgE. He will show preclinical data demonstrating that these vaccines promote neutralizing antibody responses against IL-4/IL-13/IgE and long-term protection in models of allergic asthma and anaphylaxis (the most severe clinical manifestation of allergy). Therefore, these kinoid vaccines represent promising, cost-effective, long-term therapeutic strategies for the treatment of allergic diseases.
Replay now available!
Enter your email address to access the replay.
About the speaker:
Dr. Laurent ReberLaboratory Director | Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy, France)
Dr Laurent Reber is Laboratory Director at the Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy, France) and Principal Investigator at the French National Institute of Health and Medical Research (INSERM, France). Since 2022, he is also Director of Research and Innovation at NEOVACS (France). He was recently awarded an ERC consolidator grant focused on the biology of IgE antibodies.
Dr. Reber obtained his PhD in Immunology from the University of Strasbourg (France) and his post-doctorate degree at Stanford University in Dr. Stephen Galli laboratory (CA, USA). He performs translational research on asthma and allergies, with a focus on development of novel diagnostic tools and therapeutic strategies to treat these diseases.
Comments are closed.